Inflammatory bowel disease and pregnancy

Maliszewska, Anna; Warska, Aleksandra; Cendrowski, Krzysztof; Sawicki, Włodzimierz

doi:10.5603/gp.a2017.0074

Cited by 8 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Like UC, patients might also suffer from low-grade fever in CD. The clinical course of both UC and CD is also similar, as in both the disease symptoms usually follow a characteristic pattern of periodic exacerbation followed by periods of remission [3].…”

Section: Introductionmentioning

confidence: 94%

See 1 more Smart Citation

Megacolon in Primigravida During Second Trimester: A Case Report

Fatima¹,

Mohsen²,

Waheed³

et al. 2020

COS

View full text Add to dashboard Cite

Toxic megacolon is one of the fatal complications of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). It is not very common for UC to present for the first time during pregnancy, especially with complications like toxic megacolon. Here, we have described a case of megacolon in a primigravida in late second trimester most probably due to IBD. The baby was delivered via cesarean section, and the mother was managed conservatively. Postnatal periods for both mother and baby were uneventful.

show abstract

Section: Introductionmentioning

confidence: 94%

“…UC presents with diarrhea with blood and mucus, along with cramping abdominal pain and painful passage of stool. Sometimes low-grade fever might accompany [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

Megacolon in Primigravida During Second Trimester: A Case Report

Fatima¹,

Mohsen²,

Waheed³

et al. 2020

COS

View full text Add to dashboard Cite

show abstract

“…Parece razonable continuar con monoterapia durante el embarazo para mantener la remisión, sin embargo, nunca debe ser iniciada en el embarazo dado su lenta acción y los eventos adversos asociados 43 . Metotrexato y talidomida están contraindicados por sus efectos adversos 44 .…”

Section: ) Inmunomoduladoresunclassified

Embarazo en enfermedad inflamatoria intestinal: no solo 9 meses de cuidado

Núñez

et al. 2020

Rev. méd. Chile

View full text Add to dashboard Cite

Inflammatory bowel disease during pregnancyThe prevalence of inflammatory bowel disease (IBD) increased in the last decades. Thus, the number of pregnant women with the condition is also increasing. Given that active disease itself is the main risk factor for complications during pregnancy, it is necessary to achieve a complete remission before planning a pregnancy. Also, pregnant women with IBD must be monitored noninvasively and be treated proactively, including escalated therapies, if needed, to prevent potential flares during pregnancy. Patients can undergo vaginal delivery in most forms of IBD. However, cesarean delivery is still preferable in women with a history of ileal pouch-anal anastomoses (IPAA) or active perianal disease.

show abstract

“… 1 In women, the peak onset of CD is at the age 15–24 years and for UC detection is at ages 25–34. 2 Thus, CD and UC commonly affect women in their childbearing years.…”

Section: Introductionmentioning

confidence: 99%

“…Women suffering from IBD are often concerned whether the disease itself and the required therapy might have detrimental effects on the fertility and pregnancy course, as well as postpartum development of the newborn. 2 Many patients suffering from CD/UC, require maintenance Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review therapy during pregnancy to control the disease. [3][4][5] Consequently, current clinical guidelines recommend a continuous CD/UC treatment in case of pregnancy.…”

Section: Introductionmentioning

confidence: 99%

Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review

Terjung

Schmelz

Ehehalt

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Crohn’s disease (CD) and ulcerative colitis (UC) commonly affect women in their childbearing years. Vedolizumab (VDZ) is approved for treatment of moderate-to-severe CD and UC, but there is a knowledge gap regarding its use during pregnancy. This targeted literature review describes available evidence on safety of VDZ in pregnant patients in order to offer physicians a detailed and balanced view on persistent data during their decision-making process for an individualized treatment concept. Methods: The search included literature from the MEDLINE database and abstracts of five gastroenterological conferences published until November 2019. Publications were included if pregnancy outcomes in women receiving VDZ or neonatal outcomes in newborns of women previously exposed to VDZ were reported. Results: Out of 196 initially identified records, 18 publications reporting results of five different studies were identified. In total, for 213 of 284 VDZ-exposed documented pregnancies the following pregnancy outcomes were reported: 167 live births (172 infants due to twin births), 1 stillbirth, 35 miscarriages, 10 elective terminations (1 due to detected Down syndrome). Furthermore, during pregnancy, the following complications were observed: seven cases of (pre) eclampsia, three cases of premature rupture of membranes and one case each of placenta previa, chorioamnionitis, pneumonia, first-trimester bleeding, cholestasis, sepsis, or neonatal intraventricular hemorrhage. Based on 172 infants, 30 preterm deliveries (17.4%), 9 cases of low birth weight (5.2%), 5 infections (2.9%), and 6 cases (3.8%) with congenital anomalies were reported. Conclusion: There was no evidence for safety concerns regarding pregnancy outcomes associated with VDZ therapy. Due to the limited scope of included records, further research is needed to understand the safety profile regarding the use of VDZ during pregnancy.

show abstract

Inflammatory bowel disease and pregnancy

Cited by 8 publications

References 33 publications

Megacolon in Primigravida During Second Trimester: A Case Report

Megacolon in Primigravida During Second Trimester: A Case Report

Embarazo en enfermedad inflamatoria intestinal: no solo 9 meses de cuidado

Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review

Contact Info

Product

Resources

About